Andrea Taylor, MD
Psychiatry · Durham, NCNPI 1598995029
Payments from drug & device makers
Across 177 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$574
- AbbVie$261
- Takeda Pharmaceuticals U.S.A., Inc.$249
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$242
- Neos Therapeutics, LP$214
- Bausch Health US, LLC$202
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,91298%
- Education$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 28 | $574 |
| AbbVie(2 entities) | 20 | $261 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $249 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $242 |
| Neos Therapeutics, LP | 17 | $214 |
| Bausch Health US, LLC | 10 | $202 |
| Otsuka America Pharmaceutical, Inc. | 11 | $174 |
| Lundbeck LLC | 10 | $164 |
| Adlon Therapeutics L.p. | 8 | $126 |
| Johnson & Johnson(2 entities) | 7 | $123 |
| Eisai Inc. | 5 | $86 |
| Vanda Pharmaceuticals Inc. | 5 | $80 |
| Alkermes, Inc. | 3 | $72 |
| Tris Pharma Inc | 4 | $61 |
| Brainsway USA Inc | 1 | $55 |
| Axsome Therapeutics, Inc. | 2 | $53 |
| Shire North American Group Inc | 4 | $53 |
| Merck | 2 | $31 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Ironshore Pharmaceuticals Inc. | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Corium, LLC | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
How this compares
$2,964 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 14 | $167 |
| Quetiapine Fumarate | 19 | $161 |
| Bupropion XlBupropion Hcl | 13 | $120 |
| Alprazolam | 14 | $83 |
| Trazodone Hcl | 17 | $64 |
| Clonazepam | 14 | $56 |
| Lamotrigine | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Durham
- Mark ReynoldsDurham$3.2M
- Dan BlazerDurham$1M
- Andrew KrystalDurham$754K
- Rachel DewDurham$520K
- Steven SzaboDurham$412K
- Ranjan SudanDurham$303K
- Mustafa HusainDurham$156K
- Paolo MannelliDurham$98K
- Mark ChandlerDurham$86K
- Caleb WhitenackDurham$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.